优化乙型肝炎病毒母婴传播预防项目:整合孕产妇筛查与婴儿疫苗接种后血清学检测
该研究基于2008—2022年国家免疫信息系统的真实世界数据,分析孕产妇乙型肝炎病毒筛查、新生儿免疫及婴儿疫苗接种后血清学检测,并链接医保数据库获取抗病毒治疗信息。结果显示,孕妇HBsAg和HBeAg阳性率分别从12.2%降至2.6%、从2.7%降至0.4%(趋势P均<.0001)。在22859名接受检测的高危婴儿中,HBeAg阳性母亲所生婴儿的母婴传播率高于HBeAg阴性母亲所生婴儿(6.33% vs 0.75%,P<.001);母亲HBeAg阳性与传播风险升高相关(OR 9.29),母亲抗病毒预防与风险降低相关(OR 0.28)。
要点
- 孕妇HBsAg和HBeAg阳性率在2008—2022年间分别从12.2%降至2.6%、从2.7%降至0.4%(趋势P均<.0001)。
- HBeAg阳性母亲所生婴儿母婴传播率为6.33%,高于HBeAg阴性母亲的0.75%(P<.001)。
- 母亲HBeAg阳性与母婴传播风险升高相关(OR 9.29,95%CI 6.79-12.73),母亲抗病毒预防与风险降低相关(OR 0.28,95%CI .16-.49)。
核心结论
- 在免疫人群中,母婴传播与母亲HBeAg阳性相关,并可被母亲预防措施有效阻断。
研究设计与样本
- 分析2008—2022年国家免疫信息系统中HBV携带母亲所生高危婴儿的孕产妇HBV筛查、新生儿免疫及疫苗接种后HBsAg血清学检测数据,并链接国家健康保险数据库获取母亲抗病毒治疗信息。
主要发现
- 共筛查2460218次分娩的孕产妇HBV状态。
- 2008—2022年,本土孕妇年度HBsAg阳性率从12.2%降至2.6%,HBeAg阳性率从2.7%降至0.4%(趋势P均<.0001)。
- 22859名接受PVST的高危婴儿中,HBsAg阳性/HBeAg阴性母亲所生婴儿的MTCT率为0.75%,HBeAg阳性母亲所生婴儿为6.33%(P<.001)。
- MTCT风险随母亲HBeAg阳性而升高(OR 9.29,95%CI 6.79-12.73),随母亲抗病毒预防而降低(OR 0.28,95%CI .16-.49)。
- 对于母亲HBeAg阳性的婴儿,MTCT风险与母亲出生于免疫规划时代相关(OR 1.40,95%CI 1.17-1.67)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evaluation of the impact of a hepatitis B virus (HBV) prevention program that incorporates maternal antiviral prophylaxis on mother-to-child transmission (MTCT) is limited using real-world data. METHODS: We analyzed data on maternal HBV screening, neonatal immunization, and post-vaccination serologic testing (PVST) for hepatitis B surface antigen (HBsAg) among at-risk infants born to HBV carrier mothers from the National Immunization Information System during 2008-2022. Through linkage with the National Health Insurance Database, information on maternal antiviral therapy was obtained. Multivariate logistic regression was performed to explore MTCT risk in relation to infant-mother characteristics and prevention strategies. RESULTS: In total, 2 460 218 deliveries with maternal HBV status were screened. Between 2008 and 2022, the annual HBsAg and hepatitis B e antigen (HBeAg) seropositivity rates among native pregnant women decreased from 12.2% to 2.6% and from 2.7% to 0.4%, respectively (P for both trends < .0001). Among the 22 859 at-risk infants who underwent PVST, the MTCT rates differed between infants born to HBsAg-positive/HBeAg-negative and HBeAg-positive mothers (0.75% and 6.33%, respectively; P < .001). MTCT risk increased with maternal HBeAg positivity (odds ratio [OR], 9.29; 95% confidence interval [CI], 6.79-12.73) and decreased with maternal antiviral prophylaxis (OR, 0.28; 95% CI, .16-.49). For infants with maternal HBeAg positivity, MTCT risk was associated with mothers born in the immunization era (OR, 1.40; 95% CI, 1.17-1.67). CONCLUSIONS: MTCT was related to maternal HBeAg positivity and effectively prevented by maternal prophylaxis in the immunized population. At-risk infants born to maternal vaccinated cohorts might possibly pose further risk.
引用
- Su WJ, Chen HL, Chen SF, et al. Optimization of Mother-to-Child Hepatitis B Virus Prevention Program: Integration of Maternal Screening and Infant Post-Vaccination Serologic Testing. Clin Infect Dis. 2024. PMID: 38562001. doi:10.1093/cid/ciae176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。